Recent Episodes
Watch recent episodes on
PTV News Review
Scroll Left
Scroll Right
AstraZeneca: Rob Hockney, Director of Alliance Management, Global Discovery Alliances




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: AstraZeneca: Rob Hockney, Director of Alliance Management, Global Discovery Alliances
Released on: November 01, 2006. © PharmaVentures Ltd
Visitors: You are watching a 5 minute preview.
Get more information and subscribe now
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Rob Hockney talks to Fintan Walton about the ongoing evolution of AstraZeneca's alliance management strategy and capabilities, and the increasingly important role that dedicated alliance management plays in the drug development process for big pharma and small biotech companies alike.
  • Summary
  • Transcript
  • Participants
  • Company
Rob Hockney talks to Fintan Walton about the ongoing evolution of AstraZeneca's alliance management strategy and capabilities, and the increasingly important role that dedicated alliance management plays in the drug development process for big pharma and small biotech companies alike. Rob emphasises the need for flexibility when developing an alliance management strategy and the importance of dialogue between partnering companies. Together, they examine the different metrics by which to measure alliance success and consider how termination does not have to be the end of a potentially profitable relationship. They also discuss the characteristics of an alliance that enables first-class management to make a value-generating difference. In addition, Rob highlights the essential role that alliance management plays in bridging the gap between companies with big differences in size and culture.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Rob Hockney has over 20 years experience in the pharmaceutical industry and is currently Director of Alliance Management in Global Discovery Alliances with AstraZeneca. His responsibilities have included the post-deal management process for discovery alliances within AstraZeneca and a number of key R&D relationships. Recently, Rob has been leading the development of new methodologies for the valuation of, and value realisation from, early, preclinical investments in science and technology. Rob has a discovery background, and before joining the alliances function, he headed up AstraZeneca's Enabling Bioscience and Technology group in the UK; before that he headed the Biotechnology group in Zeneca. He is a graduate of the University of Leeds in the UK, where he took a 1st in Biochemistry and a PhD in Biochemistry and Genetics.
AstraZeneca
AstraZeneca plc is a British-Swedish pharmaceutical company formed on 6 April 1999 by the remerger of Swedish Astra AB and British Zeneca Group plc. Zeneca had been part of Imperial Chemical Industries (ICI), as three divisions that were spun off from ICI on 1 June 1993. It is a public company and is listed on the London Stock Exchange, the New York Stock Exchange and the OMX exchange.